Bi­cy­cle Ther­a­peu­tics takes Roche's Genen­tech on an up to $2B im­muno-on­col­o­gy ride

Bi­cy­cle Ther­a­peu­tics — which is de­vel­op­ing a new class of chem­i­cal­ly syn­the­sized drugs de­signed to be phar­ma­co­log­i­cal­ly as ac­tive as bi­o­log­ics, yet man­u­fac­tured as small mol­e­cules —  has scored an­oth­er big part­ner: Roche’s Genen­tech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER